Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.

[1]  R. Arceci,et al.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.

[2]  P. Vyas,et al.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. , 2011, Blood.

[3]  P. Vyas,et al.  Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome , 2010 .

[4]  S. Orkin,et al.  Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. , 2010, Genes & development.

[5]  S. Orkin,et al.  miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. , 2010, Genes & development.

[6]  P. Vyas,et al.  Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi‐step model of myeloid leukaemogenesis , 2009, British journal of haematology.

[7]  J. Crispino,et al.  ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells. , 2009, Blood.

[8]  S. Antonarakis,et al.  Genotype–phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21 , 2009, European Journal of Human Genetics.

[9]  S. Izraeli,et al.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.

[10]  M. Weiss,et al.  Trisomy 21 enhances human fetal erythro-megakaryocytic development. , 2008, Blood.

[11]  P. Vyas,et al.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. , 2008, Blood.

[12]  Tomohiko Nakamura,et al.  Risk factors for early death in neonates with Down syndrome and transient leukaemia , 2008, British journal of haematology.

[13]  D. Reinhardt,et al.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. , 2008, Blood.

[14]  Sharon R. Pine,et al.  Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. , 2007, Blood.

[15]  P. Vyas,et al.  Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome , 2007, Nature Clinical Practice Oncology.

[16]  N. Nowak,et al.  Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region , 2007, Journal of Medical Genetics.

[17]  A. F. Cunha,et al.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis , 2006, Nature Genetics.

[18]  G. Xu,et al.  Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome , 2006, Leukemia.

[19]  S. Winter,et al.  Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. , 2006, The Journal of pediatrics.

[20]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Weiss,et al.  Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. , 2005, Blood.

[22]  Sharon R. Pine,et al.  GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. , 2005, Leukemia research.

[23]  P. Vyas,et al.  GATA1-Mediated Megakaryocyte Differentiation and Growth Control Can Be Uncoupled and Mapped to Different Domains in GATA1 , 2005, Molecular and Cellular Biology.

[24]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[25]  B. Göttgens,et al.  The proto-oncogene ERG in megakaryoblastic leukemias. , 2005, Cancer research.

[26]  J. Crispino,et al.  Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. , 2005, Blood.

[27]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[28]  D. Reinhardt,et al.  Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar Blasts , 2005, Klinische Padiatrie.

[29]  P. Vyas,et al.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder , 2005, British journal of haematology.

[30]  P. Vyas,et al.  Natural history of GATA1 mutations in Down syndrome. , 2004, Blood.

[31]  R. Skinner,et al.  Demographic study of leukaemia presenting within the first 3 months of life in the Northern Health Region of England , 2004, Journal of Clinical Pathology.

[32]  Y. Hayashi,et al.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. , 2003, Blood.

[33]  A. Teigler‐Schlegel,et al.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. , 2003, Blood.

[34]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[35]  R. Arceci,et al.  Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. , 2003, Blood.

[36]  Kamaleldin E Elagib,et al.  RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. , 2003, Blood.

[37]  D. Nižetić,et al.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder , 2003, The Lancet.

[38]  G. de Jong,et al.  Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[39]  A. Zipursky,et al.  Transient leukaemia – a benign form of leukaemia in newborn infants with trisomy 21 , 2003, British journal of haematology.

[40]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[41]  Nitin J. Karandikar,et al.  Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. , 2001, American journal of clinical pathology.

[42]  A. Baschat,et al.  Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21 , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[43]  F. Girodon,et al.  Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21. , 2000, Cytometry.

[44]  J. Gurney,et al.  Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. , 1996, Blood.

[45]  J. Lingrel,et al.  expression and primitive erythropoiesis-globin gene β EKLF and KLF 2 have compensatory roles in embryonic , 2007 .

[46]  George A Calin,et al.  MicroRNA fingerprints during human megakaryocytopoiesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Nasim,et al.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481 , 2006 .

[48]  J. Delabar,et al.  Molecular Mapping of Twenty-Four Features of Down Syndrome on Chromosome 21 , 1993, European journal of human genetics : EJHG.